Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against
COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies to neutralize these …

SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the
rollout of effective vaccines. Therefore, it is essential to understand the levels of protection …

The emergence of SARS-CoV-2 variants raises concerns about their resistance to
neutralizing antibodies elicited from previous infection, or from vaccination. Here we …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have been developed. However, the emergence of viral variants that are more …

Understanding the impact of prior infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to …

Many adults in India have received at least one dose of COVID-19 vaccine with or without a
prior history SARS-CoV-2 infection. However, there is limited information on the effect of …